title: [Treatment of intrathecal fentanyl-induced itch with pentazocine: a case report].
abstract: Pentazocine has activities both of kappa-opioid receptor agonist and weak micro-opioid receptor antagonist. Recent study has suggested that kappa-opioid receptor agonists have antipruritic effects. We experienced a case of pentazocine inhibiting itch evoked by intrathecal fentanyl in a patient with idiopathic pulmonary fibrosis (IPF). A 50-year-old woman with IPF was diagnosed with fallopian tube abscess and which necessitated emergency surgery. We mainly performed regional anesthetic management to prevent acute exacerbation of IPF by tracheal intubation under general anesthesia. About 30 minutes after intrathecal administration of a combination of bupivacaine and fentanyl, she began to complain of itch. Although propofol was given intravenously, pruritus still recurred. Following that, when pentazocine was administered intravenously, pruritus disappeared immediately and then never recurred. Therefore, it is suggested that pentazocine can be useful in reducing pruritus on intrathecal opioid-induced itch. Future studies are necessary to evaluate the efficacy of pentazocine for the treatment and prevention of opioid-induced itch.
authors: Masato
authors: M
authors: Hirabayashi
authors: Noritaka
authors: N
authors: Imamachi
authors: Manabu
authors: M
authors: Sakakihara
authors: Yoji
authors: Y
authors: Saito
mesh_terms: D000038:Abscess / Q000150:complications / Q000601:surgery; D000701:Analgesics, Opioid / Q000008:administration & dosage* / Q000009:adverse effects*; D000768:Anesthesia, General; D000982:Antipruritics; D004632:Emergency Medical Services; D005184:Fallopian Tube Diseases / Q000150:complications / Q000601:surgery; D005260:Female; D005283:Fentanyl / Q000008:administration & dosage* / Q000009:adverse effects*; D006801:Humans; D054990:Idiopathic Pulmonary Fibrosis / Q000150:complications; D007262:Infusions, Intravenous; D007278:Injections, Spinal; D008875:Middle Aged; D010423:Pentazocine / Q000008:administration & dosage / Q000494:pharmacology / Q000627:therapeutic use*; D011537:Pruritus / Q000139:chemically induced* / Q000188:drug therapy* / Q000517:prevention & control; D017473:Receptors, Opioid, kappa / Q000819:agonists; D016896:Treatment Outcome
chemical_list: D000701:Analgesics, Opioid; D000982:Antipruritics; D017473:Receptors, Opioid, kappa; D010423:Pentazocine; D005283:Fentanyl